Антифосфолипидный синдром - Насонов Е.Л.
ISBN 5-98216-010-5
Скачать (прямая ссылка):
26. Hartung K, Coldewey R, Corvetta A, et al. MHC gene products and anticardiolipin antibodies in systemic lupus erythematosus. Results of a multicenter study. SLE study group. Autoim-munity 1992; 13: 95—99.
27. Hashimoto H, Yamanaka K, Tokano Y, et al. HLA-DRB1 alleles and beta2 glycoprotein I-dependent anticardiolipin antibodies in Japanese patients with systemic lupus erythematosus. Clin Exp Rheumatol 1998; 16: 423—427.
28. Gulko PS, Reveille JD, Koopman WJ, et al. Anticardiolipin antibodies in systemic lupus ery-thematosus: clinical correlates, HLA associations, and impact survival. J Rheumatol 1993; 20: 1684—1693.
29. Sebastiani GD, Lulli P, Passiu G, et al. Anticardiolipin antibodies: their relationship with HLA-DR antigens in systemic lupus erythematoss. Br J Rheumatol 1991; 30: 156—157.
30. Galeazzi M, Sebastiani GD, Passiu G, et al. HLA-DP genotyping in patients with systemic lupus erythematosus: correlations with autoanti-body subset. J Rheumatol 1992; 19: 42—46.
31. Galeazzi M, Sebastiani GD, Tincani A, et al. HLA class II associations of anticardiolipin and anti-beta2 GPI antibodies in a large series of
European patients with systemic lupus erythe-matosus. Lupus 2000; 9: 47—55.
32. Arnett FC, Thiagarajan P, Ahn C, Reveille JD. Associations of anti-beta2-glycoprotein I autoanti-bodies with HLA class II alleles in three etnic groups. Arthritis Rheum 1999; 42: 268—274.
33. Wilson WA, Perez. MC, Michalski JP, Armatis P.E. Cardiolipin antibodies and null alle-les of C4 in black Americans with systemic lupus erythematosus. J Rheumatol 1988; 15: 1768— 1772.
34. Wilson WA, Scopelitis E, Michalski JP, et al. Familial anticardiolipin antibodies and C4 deficiency genotype that coexist with MHC DQB1 risk factors. JRheumatol 1995; 22: 227—235.
35. Galeazzi M, Sebatiani GD, Morozzi G, et al. HLA class II DNA typing in a large series of European patients with systemic lupus erythe-matosus. Correlations with clinical and autoanti-body subsets. Medicine 2002; 81: 169—178.
36. Sanghera DK, Kristensen T, Hamman RF, et al. Molecular basis of the apolipoprotein H (beta2-glycoprotein 1) polymorphism. Hum Genet 1997; 100: 57—62.
37. Koike T, Ichikawa K, Atsumi T, et al. Epitopes on ?2-GPIrecognized by anticardiolipin antibodies. Lupus 1998; 7: S14—17.
38. Hirose N, Williams R, Alberts AR, et al. A role for the polymorphism at position 247 of the ?2-glycoprotein 1 grene and generation of anti-?2-glycoprotein I antibodies in the antiphospho-lipid syndrome. Arthritis Rheum 1999; 42: 1655— 1651.
39. Atsumi T, Tsutsumi A, Amengual O, et al. Correlation between ?2-glycoprotein I valine/ leucine 247 polymorphism and anti-?2-glycopro-tein-I antibodies in patients with primary antiphospholipid syndrome. Rheumatology (Oxford) 1999; 38: 721—723.
40. Prieto GA, Cabral AR, Zapata-Zuniga M, et al. Valine/valine genotype at position 247 of the beta2-glycoprotein 1 gene in Mexican patients with primary antiphosphilipid syndrome: association with anti-beta2-glycoprotein-1 antibodies. Arthritis Rheum 2003; 48: 471—474.
41. De Stefano, Chiusolo P, Paciaroni K, Leone G. Epidemiology of factor V Leiden: clinical implications. Semin Thromb Hemost 1998; 24: 367—379.
SHS-OOO4.qxd 21.11.2006 16:56 Page 47
7>
ГЛАВА 2. Антифосфолипидный синдром: этиология и генетическая предрасположенность
42. Rosendaal FR, Siscovick DS, Schwartz SM, et al. Factor V Leiden (resistense to activated protein C) increases the risk of myocardial infarction in young women. Blood 1997; 89: 2871—2821.
43. Pablos JL, Caliz RA, Carreira PE, et al. Risk of thrombosis in patients with antiphospho-lipid antibodies and factor V Leiden mutation. J Rheumatol 1999; 26: 588—590.
44. Simantov R, Lo SK, Salmon JE, Sam-maritano LR, Silverstein RL. Factor V Leiden increase risk of thrombosis in patients with antiphospholipid syndrome. Thromb Res 1996; 84: 361—365.
45. Dizon-Townson D, Hutchison C, Silver R, Branch DW, Ward K. The factor V Leiden mutation which predisposes to thrombosis is not common in patients with antiphospholipid syndrome. Thromb Haemost 1995; 74: 1029—1031.
46. Montaruli B, Borchiellini A, Tamponi G, et al. Factor V Arg 506 Gln mutation in patients with antiphospholipid antibodies. Lupus 1996; 5: 303—306.
47. Chopra M, Koren S., Greer WL, et al. Factor V Leiden, prothrombin gene mutation, and thrombosis risk in patients with antiphospholipid antibodies. J Rheumatology 2002; 29: 1683— 1688.
48. Решетняк ТМ, Патрушев ЛИ, Стука-чева ЕА, Мирошников АИ, Тихонова ТЛ, Насонов ЕЛ, Алекберова ЗС. Мутация Leiden, G20210A в гене протромбина и антифосфли-пидные антитела при системной красной волчанке и антифосфолипидном синдроме. Терапевт. архив, 2000; 5: 34—38.
49. Dawson SJ, Hamsten A, Wiman B, et al. Genetic vriation at the plasminogen activator inhibitor-1 locus is associated with altered levels of plasma plasminogen activator inhibitor-1 activity. Arterioscler Thromb 1991; 11: 183—190.
50. Mansfield MW, Stickland MH, Grant PJ. Plasminogen activator inhibitor-1 (PAI-1) promoter polymorphism and coronary artery disease in non-insulin-dependent diabetes. Thromb Haemost 1995; 74: 1032—1034.
